Relay Therapeutics appoints Sekar Kathiresan, M.D. to Board of Directors
Relay Therapeutics, Inc.
Dr. Kathiresan appointed as class III director effective July 25, 2022, filling a newly created vacancy expanding board to eight members.
He is co-founder and CEO of Verve Therapeutics (VVTA) and serves on its board; previously director at MGH Center for Genomic Medicine and Broad Institute.
He will receive an initial option grant for 71,881 shares vesting over 36 months, plus standard non-employee director compensation.
Also appointed to the Nominating and Corporate Governance Committee.
On July 25, 2022, the board of directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Sekar Kathiresan, M.D. to the Board as a class III director to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Sekar Kathiresan was appointed as Director at Relay Therapeutics, Inc..
Action
appointed
Role
Director
Exact text from the filing
On July 25, 2022, the board of directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Sekar Kathiresan, M.D. to the Board as a class III director to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7) to eight (8) directors.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.